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Given that foods and nutrients have been shown to influence the pharmacokinetics of drugs, drugs may cause changes in the 
nutritional status of patients and their response to a given drug. Food‑drug interactions are particularly relevant for drugs used 
to treat neurological and psychological diseases. This review provides an overview of food‑drug interaction in the treatment of 
neurological and psychological diseases. A  literature search was carried out by collecting data from different reviews, reports, 
and original articles on general or specific drug interactions with food, in patients with a variety of neurological and psychological 
diseases. Based on our review, we found that food‑drug interactions may alter the expected impact of drug, or cause the 
development of a  drug toxicity. Nutritional status of the patients may also be affected, particularly a  change in body weight 
caused by a change appetite. Metabolism, absorption, and excretion of foods may also be altered, and nutritional insufficiencies 
may occur. Recent studies show that diet can have a strong influence on gut microbiota and thus, alter drug pharmacokinetics. 
Therefore, microbiota alterations should also be considered while assessing food‑drug interactions. Knowledge of food‑drug 
interactions is critical for improving health of patients with neurological and psychological diseases, and also for improving 
effectiveness of treatments.
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INTRODUCTION
Various drugs are used in the treatment of acute 
and chronic diseases. However, it is important to take 
the drugs safely and effectively during therapy. Al‑
though concerns about drug‑drug interactions fre‑
quently come to mind, interactions may also occur 
between drugs and foods, particularly with plants. 
However, studies on food‑drug interactions are more 
limited than those on drug‑drug interactions (Bushra 
et al. 2011, Otles and Senturk 2014). A food‑drug inter‑
action is the consequence of a physical, chemical, or 
physiologic relationship between a drug and a product 
consumed as food or a nutrient present in a botanical‑
ly‑derived food or dietary supplement. The influence of 
dietary substances on drug effects depends on numer‑
ous variables, including physicochemical properties 
of the drug, and enzymes and transporters present in 
the gastrointestinal tract. Food‑drug interactions may 
affect pharmacokinetic and pharmacodynamic proper‑
ties of drugs (Choi and Ko 2017).
Food‑drug interactions are particularly relevant 
for neurological and psychological diseases. In gener‑
al, neurological or psychological diseases involve the 
brain, brainstem, spinal cord or peripheral nervous 
system disorders, as well as systemic disorders of the 
muscles (Aksoy 2016). Depression, schizophrenia, Par‑
kinson’s disease, Alzheimer’s, epilepsy, bipolar dis‑
order, general anxiety disorder, and sleep problems 
are all included in this disease group. Common drug 
classes used to treat these conditions include anticon‑
vulsants for epilepsy, antipsychotic drugs for schizo‑
phrenia, dopaminergic agents for Parkinson’s, and an‑
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tidepressants for depression as well as panic attacks. 
In each drug group, different food‑drug interactions 
may occur. Awareness of interactions with these drugs 
is important in terms for the health of the patients as 
well as the effectiveness of the treatment (WHO 2006, 
Otles and Senturk 2014, FDA 2016). To examine this, the 
present review is focused on providing an overview of 
interactions of the main drug groups used in neuro‑
logical and psychological diseases (Fig. 1) with food/
nutrients, and impacts of the drugs on body weight 
and appetite.
A literature research was carried out by collecting 
recent data from different reviews, reports, and origi‑
nal articles on general or specific drug interactions with 
food in neurological and psychological diseases.
ANTICONVULSANT/ANTIEPILEPTIC DRUGS
Anticonvulsant drugs are commonly used in the 
treatment of epilepsy, and are used to control seizures. 
The main purpose of anticonvulsant treatment is to re‑
duce brain damage by preventing the onset of seizures 
(Aksoy 2016, Kirmani et al. 2016).
Common anticonvulsant drugs include phenytoin, 
barbiturates i.e phenobarbital, primidone, carbamaz‑
epine, sodium valporate (VPA), felbamate, topiramate, 
and zonisamide. There are many studies showing that 
these drugs interact with food and nutrients (Arslan et 
al. 2009, Hosseinpour et al. 2007, Lee and Yu 2015).
The anticonvulsant drugs, particularly phenytoin, 
barbiturates, carbamazepine, and VPA, may cause vi‑
tamin D deficiency by increasing vitamin D metabolism 
in the liver. Vitamin D deficiency may cause calcium 
absorption in the small intestine to deteriorate, an in‑
crease in calcium extraction from the bones, and a re‑
duction in bone mineral density. Chronic anticonvul‑
sant drug use may cause bone loss and osteomalacia in 
adults, and rickets in children (Baek et al. 2014, Başoğlu 
et al. 1999, Hosseinpour et al. 2007, Vestergaard 2015). 
In a study of children with epilepsy who receive anti‑
convulsant treatment, there was a negative correlation 
between plasma 25 hydroxy vitamin D levels and drug 
use, such that 82.5% of children developed a new vita‑
min D deficiency after initiation of treatment (Lee and 
Yu 2015). Similarly, in a separate study of children with 
epilepsy on long‑term (>1 year) antiepileptic drugs, 
55 Malaysian children (22.5%) had vitamin D deficien‑
cy and another 48 (19.7%) had vitamin D insufficiency. 
Polytherapy (>1), age (>12 years old), sun exposure time 
(30–60 min/day or <30 min/day) were identified as sig‑
nificant risk factors for vitamin D deficiency (Fong et 
al. 2016). 
Anticonvulsant drugs may compete with biotin in 
the human intestine, and inhibit the transport of bi‑
otin by influencing the substrate transport system in 
the enterocyte brush border membrane layer. In addi‑
tion, anticonvulsant drugs may increase the excretion 
of biotin by accelerating biotin catabolism and me‑
tabolism which may cause biotin deficiency, as well as 
lower serum and liver biotinides activity (Arslan et al. 
2009, Mock et al. 1998, Pronsky and Crowe 2012, Rath‑
man et al. 2003). In a study of rats receiving carbamaze‑
pine treatment, supplementation with 0.06 g/kg biotin 
was associated with a reduction in plasma free biotin, 
and pyruvate carboxylase and acetyl CoA carboxylase 
enzyme activity. Supplementation with 6 mg/kg bio‑
tin was associated with an increase in free biotin, and 
a prevention of the reduction in decrease in pyruvate 
and acetyl CoA carboxylase enzyme activity. Also the 
biotin supplementation showed positive effect (Arslan 
et al. 2009). 
Several studies have demonstrated that an increase 
in serum homocysteine levels among patients receiving 
anticonvulsant treatment may cause a deficiency in fo‑
lic acid, vitamin B6, and vitamin B12, which may, in turn, 
increase risk for cardiovascular diseases (Karabiber et 
al. 2003, Sener et al. 2006). The type of anticonvulsant 
drug used is effective at modulating homocysteine, B12, 
and folic acid levels. In particular, there was no differ‑
ence between homocysteine, B12, and folic acid levels 
in oxcarbazepine‑treated epilepsy patients compared 
to controls (Rezaei et al. 2017). However, meta‑anal‑
yses show that homocysteine levels are significantly 
higher among patients receiving carbamazepine and 
sodium VPA relative to control, whereas serum folate 
levels are significantly lower in patients receiving car‑
bamazepine compared to controls. On the other hand, 
carbamazepine treatment is associated with a reduc‑
Fig. 1. Main classes of drugs used to treat neurological and psychological 
diseases (e.g. depression, Parkinson’s disease, schizophrenia). 
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tion in serum folate levels, and treatment with sodi‑
um valproate is associated with a reduction in serum 
vitamin B12 levels (Gorjipour et al. 2013, Ni et al. 2014). 
The patient group treated with VPA group had higher 
serum levels of homocysteine compared to the control 
group (Ni et al. 2014). In addition, patients receiving 
VPA had significantly lower serum folate levels relative 
to controls (Bächle et al. 2015). 
Several studies have examined methylenetetrahy‑
drofolate reductase (MTHFR) gene polymorphism and 
homocysteine levels among epileptic patients receiv‑
ing antiepileptic drug treatment (Di Rosa et al. 2013, 
Munisamy et al. 2015, Semmler et al. 2013). A differ‑
ence in the methylation levels of MTHFR amplicon was 
observed between antiepileptic drug‑treated patients 
with epilepsy and controls. There was also a positive 
correlation between serum folate levels and periph‑
eral blood MTHFR amplicon methylation status. Thus, 
antiepileptic drug monotherapy may affect one car‑
bon metabolism, which may subsequently lead to hy‑
po‑methylation in certain regions of deoxyribonucleic 
acid (Bächle et al. 2015). Munisamy et al. (2015) found 
a significant increase in mean homocysteine levels in 
epileptic patients receiving anti‑epileptic drug mono‑
therapy (i.e. phenytoin carbamazepine or VPA), as well 
as a reduction in mean folic acid and vitamin B12 among 
toxicity and non‑toxicity groups. For patients with ep‑
ilepsy who also had the MTHFR C677T polymorphism, 
particularly those with the TT genotype, homocyste‑
ine levels were higher and folic acid and B12 levels were 
lower compared to control groups (Munisamy et al. 
2015). Di Rosa et al. 92013) found higher homo cysteine 
levels in patients with MTHFR polymorphism. In con‑
trast, results of a study of 498 antiepileptic drug‑treat‑
ed epilepsy patients by Semmler et al. (2013) suggest 
that folate and vitamin B12 play important roles in the 
development of hyper‑homo cysteinemia. Importantly, 
in that study, there was no relationship between genes 
and risk of developing hyper‑homocysteinemia during 
antiepileptic drug treatment. Given these results, sub‑
sequent studies have investigated the effects of vita‑
min supplement on homocysteine levels (e.g. Bochyńs‑
ka et al. 2012, Chandrasekaran et al. 2017). One study 
examined the effects of 0.4 mg/day folate, 50 mg/day 
vitamin B6, and 100 mcg/day vitamin B12 supplemen‑
tation among patients receiving Carbamazepine and 
VPA treatment. After one year of sup plementation, 
the authors observed a significant de cline in the Beck 
Depression Inventory, in the hyper homocysteinemia, 
and in seizure frequency observed (Bochyńska et al. 
2012). In another study of children receiving carba‑
mazepine and phenytoin treatment, supplementation 
with 5 mg/day folic acid for one month was associat‑
ed with an increase in serum homocysteine levels, and 
a reduction in B12 and folic acid levels (Chandrasekaran 
et al. 2017). Supplementation was also associated with 
a reduction in plasma homocysteine concentrations 
in the study group (Chandrasekaran et al. 2017). Giv‑
en these results levels of vitamin B6, vitamin B12, and 
folic acid should be monitored among patients receiv‑
ing anticonvulsant drugs, and supplementation may 
be beneficial (Bochyńska et al. 2012, Chandrasekaran 
et al. 2017). On the other hand, excess intake of fo‑
lic acid may reduce the effectiveness of the drug. In 
a case study, it was demonstrated that 5 mg/day folic 
acid supplementation was associated with a reduction 
in serum phenytoin concentration, and an increase 
in number of seizure attacks (Seligmann et al. 1998). 
Phenytoin and phenobarbital may also affect vitamin 
K metabolism, leading to deficiency (Elmacioğlu 2007). 
VPA is a drug that is routinely used during epilepsy 
attacks. VPA administration may cause carnitine de‑
ficiency by reducing endogenous carnitine synthesis 
via enzyme inhibition, inhibition of the intracellular 
carnitine transport, and/or by reducing absorption 
of free carnitine and acyl‑carnitine (Bykov et al. 2004, 
Moreno et al. 2005, Wu et al. 2004). Carnitine deficien‑
cy was found in approximately 17% of patients with 
epilepsy and was significantly associated with carni‑
tine‑free enteral formula only by tube feeding (Fukuda 
et al. 2015). At the same time, plasma VPA concentra‑
tions were slightly higher in carnitine deficient rats 
than in controls (Katayama et al. 2016). In one study 
of schizophrenic patients receiving VPA treatment, 
supplementation of 30 mg/kg levo‑carnitine supple‑
mentation was associated with an increase in serum 
carnitine levels relative to baseline (Nakamura and 
Nagamine 2015). This increase was accompanied by 
a general recovery in mental status. Based on these re‑
sults, the authors suggest that carnitine supplementa‑
tion may be beneficial among schizophrenic patients 
receiving VPA (Nakamura and Nagamine 2015). Other 
studies have shown that VPA is influenced by high fat 
intake. For example, in one study, rats were given a die 
that included high fructose (45% fructose) as well as 
high fat diet (20% fat) for 30 days. Animals receiving 
the high fat and fructose diets, as well as VTA, demon‑
strated deregulated lipid metabolism, loss of insulin 
sensitivity, increased alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) levels, en‑
hanced CYP2E1 activity and oxidative damage, and re‑
duced cellular antioxidants (Sathiya Priya et al. 2016). 
Moreover, a study of patients receiving VPA treatment 
linked a high‑fat diet (77.5% fat) with increased hep‑
atotoxicity, via modulation of mitochondrial β‑oxida‑
tion. Based on these results, some authors have sug‑
gested that patients on VPA should avoid a high‑fat 
diet (Zhang et al. 2014). 
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Another problem that may be observed during VPA 
treatment is hypocalcemia. Although hypocalcemia is 
also observed following phenytoin treatment, this ef‑
fect is thought to be caused by phenytoin’s inhibition 
of vitamin D hydroxylation. VPA, on the other hand, it 
thought to affect calcium via a pathway that is separate 
from vitamin D. It has been proposed that metabolites 
of VPA cause hypocalcemia by binding with calcium 
(Davison et al. 2011).
In addition to changes in calcium, long‑term VPA 
treatment may cause a reduction in serum levels of zinc, 
hair zinc and copper levels (Armutcu et al. 2004, Yilmaz 
et al. 2009). However, one study suggested that, even if 
serum zinc levels were low or normal among patients 
treated with VPA, the drug did not significantly affect 
activity of serum zinc, biotin, and biotinidase (Cas‑
tro‑Gago et al. 2011). 
VPA has also been shown to interact with soy‑
beans. In one study, rats were pretreated with either 
150 mg/kg or 500 mg/kg of soy extract for five days. 
VPA Cmax values were decreased to 57% for those pre‑
treated with 150 mg soy, and to 65% for those treated 
with 500 mg. Of note, gamma aminobutyric acid (GABA) 
concentrations in the brain were increased within 
5 min after VPA injection. In the soy‑treated group, 
concentrations of GABA in the brain were significantly 
inhibited throughout the entire study period; however, 
plasma levels of GABA were not significantly different 
between the treatment and control groups (Marahatta 
et al. 2014). 
Anticonvulsant drugs were associated with levels 
of trace elements. In a study conducted in 307 patients 
with epilepsy receiving treatment with either conven‑
tional or newer antiepileptic drugs and 42 controls, it 
was found that trace element status was significantly 
altered among both patient groups compared to the 
control group. Compared to controls, patients receiv‑
ing levetiracetam had higher zinc, selenium, copper, 
iron, aluminum, cadmium, cobalt, and nickel levels, 
whereas levels of manganese and lead did not differ 
between groups. Similar elevations in metals were ob‑
served in other monotherapy groups, except for levels 
of nickel, iron, lead, and selenium (Sarangi et al. 2014).
Anticonvulsant drugs can also impact on body 
weight. Felbamate, topiramate and zonisamide are 
associated with a decrease in body weight. Phenytoin 
does not have impact on body weight, whereas gab‑
apentin, pregabalin, carbamazepine and VPA may in‑
crease body weight by increasing appetite (Antel and 
Hebebrand 2012, Ben‐Menachem 2007, Pronsky and 
Crowe 2012). One study found that the increase in 
bodyweight among patients taking VPA may be caused 
by a decrease in serum glucose levels, an increased de‑
sire to eat, increased energy intake, fasting, overeat‑
ing, depression, and increased glucagon‑like peptide‑1 
(Martin et al. 2009).
Anticonvulsant drugs can also interact with alcohol 
by altering the metabolism or effects of alcohol and/or 
the drug. Some of these interactions can occur even at 
moderate drinking levels and cause adverse health ef‑
fects for the drinkers. Thus, it is suggested to avoid tak‑
ing anticonvulsant drugs with alcohol (Vernon 2013). 
DOPAMINERGIC AGENTS 
Levodopa 3–4 dihydroxy phenyl alanine is the pre‑
cursor of dopamine and is used in pharmacological 
treatment of Parkinson’s disease (PD). Dopaminergic 
agents used in treatment can precursors of dopamine 
with decarboxylase inhibitor carbidopa/levodopa, do‑
pamine agonists, bromocriptine, and pergolide (Akbu‑
lut 2009).
Methylation of levadopa is catalyzed by cate‑
chol‑O‑methyltransferase, which drives the production 
of S‑adenosyl homocysteine. Levadopa can be revers‑
ibly hydrolyzed to homocysteine. Folate, vitamin B6, 
and vitamin B12 are all cofactors for the production of 
homocysteine enzymes, and deficiencies in any one of 
these can lead to elevated homocysteine (Qureshi et 
al. 2008, Rozycka et al. 2013). At the same time, a poly‑
morphism in the MTHFR and methylenetetrahydrofo‑
late dehydrogenase 1 (MTHFD1) genes affecting folate 
and homocysteine metabolism may enhance the effect 
of levodopa on homocysteine among PD patients, and 
cause an additional elevation in concentration of homo‑
cysteine (Oliveira et al. 2017, Rozycka et al. 2013). High 
concentrations of homocysteine in PD may have det‑
rimental effects on dopaminergic neurons (Rozycka et 
al. 2013). One study reported significantly higher levels 
of homocysteine among PD patients receiving levodopa 
treatment. Further, patients with PD had higher aortic 
strain and aortic stiffness index, which were correlat‑
ed with higher serum homocysteine levels. Among PD 
patients, there was also a negative correlation between 
aortic distensibility and serum homocysteine levels 
(Günaydın et al. 2016). In a study conducted on 60 PD 
and 82 healthy subjects treated with levodopa, PD pa‑
tients were more likely to show the MTHFR TT677 gene 
polymorphism and higher homocysteine levels com‑
pared to controls. At the same time, total coen zyme Q10 
(CoQ10) was significantly lower in PD patients than in 
healthy subjects, and as consequence, percent content 
of oxidized versus total CoQ10 was higher in the pa‑
tient group compared to controls. PD patients with the 
TT677 polymorphism exhibited the highest levels of 
homocysteine and percent content of oxidized versus 
total CoQ10. TT677 genotype and levodopa daily dose 
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were independent ly and directly correlated with levels 
of homocysteine and CoQ10 (Gorgone et al. 2012). One 
recent meta‑analysis summarized results of 15 studies 
in which plasma homocysteine B12 and folate levels and 
cognitive function were assessed in PD patients, who 
were divided into two groups: those with cognitive im‑
pairment (PDCI) and those without cognitive impair‑
ment (PDNC). Results of the meta‑analysis demonstrate 
that, overall, homocysteine concentration is high‑
er among PD patients than among healthy controls. 
Within PD patients, there were significant differences 
between PDCI and PDCN groups for homocysteine, vi‑
tamin B12, and folate. In particular, levels of homocys‑
teine were higher, and levels of vitamin B12 and folate 
were lower among PDCI patients compared to PDCN pa‑
tients (Xie et al. 2017). Therefore, adequate intake of 
folate, vitamin B6 and vitamin B12 in diet may reduce the 
impact of levodopa by preventing an increase in homo‑
cysteine levels (Qureshi et al. 2008). 
Intake of levodopa with foods, the time of ingestion 
of a meal, fat, fiber, ascorbic acid may change the ef‑
fectiveness of drug in the body (Fernandez et al. 2010). 
Patients receiving levodopa treatment should be mon‑
itored for food intake with the drug, carbohydrate and 
protein content of the meals, and associated micronu‑
trient deficiencies. Patient diets should be regulated in 
accordance with the meal that the drug is taken (Ak‑
bulut 2009, Ismail 2009). Absorption rate of levodopa 
may increase during fasting and its absorption may de‑
crease or delay as a result of its intake with particular 
foods (Akbulut 2009). Nutritional content of the meals 
also has an impact on levodopa. In particular, protein 
may inhibit the absorption of levodopa by modulating 
gastric discharge time and the transport mechanism 
of the drug. At the same time, the neutral amino ac‑
ids (e.g. valine, isoleucine, tryptophan, phenylalanine, 
tyrosine) may prevent levodopa from crossing the 
blood brain barrier by competing with the drug. Thus, 
levodopa should not be taken in conjunction with 
a high‑protein diet (Akbulut 2009, Aksoy 2016, Ismail 
2009). Moreover, high carbohydrate intake causes an 
increase in insulin secretion which may cause a reduc‑
tion in the neutral amino acids, and in turn, cause an 
increase in effectiveness levodopa (Akbulut 2009). One 
study examined a group of PD patients taking amino 
acid supplements 60 minutes after lunch and 60 min‑
utes after dinner (for a total daily dose of 16 g) each 
time at least 60 minutes before the following levodopa 
administration for six months. The control group re‑
ceived placebo according to the same procedure. The 
authors observed a significant increase in mini‑nutri‑
tional assessment scores in the group receiving both 
amino acid supplements and levodopa treatment. 
In both groups, there was a decrease in Quantita‑
tive Insulin Sensitivity Index after six months. After 
six months of supplementation, there were no changes 
in low‑density lipoprotein (LDL) and high density li‑
poprotein (HDL) cholesterol levels. However, oxidized 
glutathione levels decreased by 28% over time in the 
intervention group, but increased by 55% in the place‑
bo (Cucca et al. 2015).
In one study, administration of a banana juice 
(a mixture of fresh banana and water) was associated 
with reduced bioavailability of levodopa by drug‑food 
interaction in rats. In particular, banana juice was as‑
sociated with a significant decrease in Cmax of levodo‑
pa. Interestingly, however, administration of levodopa 
with a commercial beverage containing 10% banana 
juice resulted in no significant change in Cmax. Based 
on these results, the authors concluded that patients 
should be advised against mixing levodopa and fresh 
banana juice (Ogo et al. 2005). 
Besides the impact of foods on levodopa, this drug 
may also cause specific nutritional deficiencies. In‑
deed, nutritional deficiencies are frequently reported 
among patients with PD. Administration of levodopa 
and carbidopa may create a deficiency by inhibiting the 
kynurenine hydrolase enzyme that takes part in oxida‑
tive way of the tryptophan, and subsequently prevent 
the synthesis of niacin (Bender et al. 1979). 
ANTIDEPRESSANTS
Psychotropic drugs are a large group of medications 
that affect the nervous system through different mech‑
anisms. Patients with depression and bipolar disorder 
are treated with a variety of psycho‑pharmaceuticals. 
Among these pharmaceuticals are antidepressants, 
such as selective serotonin reuptake inhibitors, sero‑
tonin norepinephrine reuptake inhibitors, monoamine 
oxidase inhibitors, tricyclic antidepressants and a vari‑
ety of antipsychotic drugs (Ornoy et al. 2017, Yohn et 
al. 2017).
Selective Serotonin Reuptake Inhibitors (SSRIs)
SSRIs inhibit serotonin reuptake in raphe nuclei 
neurons, and chronic treatment results in an increase 
in serotonin levels throughout the brain (Yohn et 
al. 2017). Fluoxetine is one of the most frequently 
prescribed SSRIs. In one study of patients receiving 
fluoxetine treatment, hypoglycemia was observed 
72 hours after taking the drug, likely due to an in‑
crease in blood insulin levels (Deeg and Lipkin 1996). 
In another study, there was significant reduction in 
bodyweight and visceral adipose tissue after 12 weeks 
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of fluoxetine treatment (Aggarwal et al. 2016). A re‑
view reported that SSRIs affected bodyweight in the 
short term, but not the long term (Reekie et al. 2015). 
However, the effects of SSRIs on body weight may 
not be uniform across individuals. Given the impor‑
tance of adequate nutrition in early life, there may be 
long‑term effects of early malnutrition on develop‑
ment of the serotoninergic system. For example, one 
study showed a reduction in food intake and weight 
gain with chronic treatment of citalopram among 
well‑nourished rats, but not in early malnourished 
rats even in their adult stage (Barreto Medeiros et al. 
2002). On the other hand, a case report demonstrated 
that SSRI treatment could be beneficial to control ep‑
isodes of nocturnal eating/drinking disorder, poten‑
tially by improving sleep habits (Miyaoka et al. 2003). 
Moreover, SSRI treatment combined with aspirins 
or anti‑nonsteroidal anti‑inflammatory drugs have 
been shown to risk of increase upper gastrointestinal 
bleeding (Jiang et al. 2015, Yuan et al. 2006), which 
potentiality alters food intake – particularly among 
the elderly. 
Sertraline and Paroxetine have been linked to higher 
LDL cholesterol, and long‑term treatment may increase 
risk of cardiovascular disease (Wei et al. 2009). 
At the same time, a reduction of serum copper lev‑
el by 14% has been reported among patients receiving 
citalopram treatment (Schlegel‑Zawadzka and Nowak 
2000). 
Monoamine Oxidase Inhibitors (MAOIs) 
The earliest drugs found to successfully treat de‑
pression were MAOIs. MAOIs inhibit the oxidation of 
monoamines and ultimately result in increased extra‑
cellular levels of serotonin, norepinephrine, and dopa‑
mine throughout the brain (Yohn et al. 2017). Although 
MAOIs are very effective in treatment of the depressive 
diseases, studies have reported adverse effects such as 
hypertensive attacks, as a result of a drug interaction 
with foods containing tyramine (Pronsky and Crowe 
2012, Volz and Gleiter 1998). Tyramine is a sympath‑
omimetic agent that has an indirect impact on blood 
pressure when ingested concurrently with an MAOI. In 
the presence of an MAOI, tyramine digestion cannot 
occur and the tyramine participates in the circulation 
is taken by adrenergic neurons and causes a hyperten‑
sive attack (Flockhart 2012). For this reason, consump‑
tion of food containing tyramine should be avoided 
(Aksoy 2016, Pronsky and Crowe 2012).
The MAOI phenelzine may cause a deficiency, by 
also creating pyridoxal hydrazine without enzymatic 
effect and preventing vitamin B6 from turning into an 
active form (Aksoy 2016). One study found that the ac‑
tive form of vitamin B6 pyridoxal phosphate decreased 
by a rate of 54% among patients receiving phenelzine 
(Malcolm et al. 1994). 
The MAOIs in the hydrazine class, including 
phenelzine and isocarboxazide, may cause hypogly‑
cemia and an increase in body weight (McIntyre et 
al. 2006, Pronsky and Crowe 2012). These effects may 
occur via an increase in serotonin that increases the 
amount of glucose entering the brain, and/or increas‑
ing the glucose excretion rate. The net effect is a re‑
duction in blood glucose levels, which may cause an 
increase in bodyweight by increasing appetite and 
changing the energy balance (Pronsky and Crowe 2012, 
Ruetsch et al. 2005).
Tricyclic Antidepressants (TCAs) 
TCAs were developed in the mid‑1950s, with proven 
effectiveness, and are used in the treatment of major 
depression. TCAs affect the serotonergic and norad‑
renergic systems by blocking the serotonin and nor‑
epinephrine transporters (Ornoy et al.2017, Yohn et al. 
2017). The TCA group includes: amitriptyline, amoxap‑
ine, clomipramine, desipramine, doxepin, imipramine, 
nortriptyline, and protriptyline (Ornoy et al. 2017).
High dietary fiber intake may decrease absorption 
of the TCA amitriptyline, thereby decreasing the drug’s 
activity (Pronsky and Crowe 2012). Therefore, con‑
sumption of high fiber foods, including legumes, fish, 
meat, and vitamin C‑rich foods, may cause a decrease in 
the absorption of amitriptyline (Ismail 2009). 
TCAs may also cause a decrease in the plasma tryp‑
tophan concentration and an increase in the con‑
centration of tryptophan in the brain (Eriksson and 
Walinder 1998). Low plasma tryptophan values have 
been observed after only six months after treatment 
(Fekkes et al. 1997).
TCAs, especially amitriptyline, may cause increas‑
ing in body weight by stimulating hunger, increasing 
carbohydrate consumption, and by influencing the en‑
ergy balance (Ruetsch et al. 2005). These effects may 
vary depend on the dosage of the drug. 
ANTIPSYCHOTIC DRUGS
Antipsychotic drugs are used for the treatment of 
psychosis, depression, anxiety, bipolar disorders and 
obsessive‑compulsive disorders. They affect the brain 
by blocking dopamine receptors and reducing dopa‑
mine effects. Antipsychotic drugs are divided into 
first (i.e. typical) and second (i.e. atypical) genera‑
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tion. Typical antipsychotics include: chlorpromazine, 
fluphenazine, haloperidol, loxapine, perphenazine, pi‑
mozide, thioridazine, thiothixene, trifluoperazine, and 
triflupromazine. The atypical antipsychotics include: 
aripiprazole, clozapine, olanzapine, quetiapine, and 
ziprasidone (Ornoy et al. 2017).
Antipsychotic drugs may cause an increase in ap‑
petite without affecting energy consumption, and may 
thus cause an increase in body weight (Aksoy 2016, 
Pronsky and Crowe 2012, Reekie et al. 2015). In one 
study, clozapine treatment for at least one year was 
associated with an increase in body mass index (BMI), 
and the increase in BMI was higher among patients 
with the polymorphisms in the leptin gene and 5‑hy‑
droxytryptamine receptor 2C (HTR2C) gene (Kang et 
al. 2014).
One study documented a significant increase in BMI 
after 13 weeks of oral risperidone or flupenthixol treat‑
ment (Emsley et al. 2015). However, after antipsychotic 
treatment for 16 weeks, the mean change in BMI was 
‑1.9% for the intervention group and +0.6% for the con‑
trol group. Further, the difference in BMI from baseline 
was associated with duration of illness and a metabolic 
risk index, suggesting that healthy nutrition and physi‑
cal activity may be effective in controlling body weight 
during treatment (Magni et al. 2017). 
Second generation antipsychotics have been shown 
to influence blood glucose and lipids (Aksoy 2016). In 
a study carried out on obese schizophrenic patients 
receiving clozapine treatment, serum triglyceride and 
total cholesterol/high‑density lipoprotein (HDL) cho‑
lesterol levels were higher than observed in a control 
group who did not receive the drug treatment. In ad‑
dition, those taking clozapine showed a higher high 
homeostatic model assess ment (HOMA) index and 
lower insulin sensitivity, compared to controls (Wu 
et al. 2008). The observed effect of clozapine on blood 
glucose may derives from its negative impact on the 
pancreas, and may cause hyperglycemia by modulat‑
ing glucose metabolism. Blood glucose levels appear 
to be increased most dramatically by the antipsychotic 
clozapine, followed by olanzapine, quetiapine, risperi‑
done and ziprasidone. These drugs may also cause an 
increase in risk of cardiovascular disease by influenc‑
ing triglyceride, HDL cholesterol, and low‑density lipo‑
protein (LDL) cholesterol (Aksoy 2016). 
Antipsychotic drugs can also interact with micro‑
nutrients. The antipsychotic chlorpromazine thorozin 
has been shown to increase riboflavin excretion and 
may therefore cause riboflavin deficiency. Chloroprom‑
azine thorozin may also cause vitamin B12 deficiency 
(Elmacioğlu 2007, Pronsky and Crowe 2012). Anoth‑
er study found that serum levels of the antipsychot‑
ic fluphenazine (permitil, prolixin) decreased by 25% 
when taken with ascorbic acid supplementation (Dys‑
ken et al. 1979). 
Constipation is a recognized side effect of the second 
generation antipsychotic clozapine, depending on the 
movements of the smooth muscle in the intestinal wall. 
Therefore, patients taking clozapine should maintain 
sufficient water and fiber intake (Elmacioğlu 2007).
While ziprasidone should be taken with foods, the 
other drugs should be taken on an empty stomach. In 
addition, it is necessary to avoid alcohol and caffeine 
use with antipsychotic drugs (Food and Drug Adminis‑
tration 2016).
SLEEPING PILLS
Sleeping pills ease sleeping problems by decelerating 
brain activity. They are used to treat problems in fall‑
ing or staying asleep. Eszopiclane and zolpidem are ex‑
amples of sleeping pills (Food and Drug Administration 
2016).
Patients should avoid taking sleeping pills with al‑
cohol. When taken with caffeine, sleeping pills may in‑
crease anxiety, and the effectiveness of the sleeping pills 
may decrease (Food and Drug Administration 2016, Is‑
mail 2009).
According to the US Food and Drug Administration 
(FDA), sleeping pills should not be taken with a meal 
or immediately after a meal (FDA 2016). Indeed, one 
study found lower plasma zolpidem levels 20 minutes 
to 3 hours following a dose in those receiving a high 
fat diet compared to a fasted state. After four hours, 
however, those on the high fat diet demonstrated 
higher plasma zolpidem levels (Greenblatt et al. 2013). 
Further, studies have reported an interaction between 
zolpidem and St John’s wort (SJW). In one study, four‑
teen healthy male subjects received a single 10 mg oral 
dose of zolpidem followed by 300 mg orally, three times 
a day of SJW, for 14 days. After repeated administra‑
tion of SJW, there was a reduction in mean values of 
Cmax for zolpidem. This effect SJW on the pharmacoki‑
netics of zolpidem has not previously been reported. 
Repeated administration of SJW decreased the plasma 
concentration of zolpidem, potentially by enhancing 
CYP3A4 activity (Hojo et al. 2011). 
Triazolam, another drug used to treat insomnia, 
has been shown to interact with grapefruit juice. Huk‑
kinen et al. (1995) demonstrated that triazolam taken 
with 250 ml of grapefruit juice resulted in an increase in 
peak concentration of the drug, as well as an increase in 
drowsiness (Hukkinen et al. 1995). 
The aforementioned food‑drug interactions in neu‑
rological and psychological diseases are summarized in 
Table I.
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Table I. Summary of food‑drug interactions in neurological and psychological diseases.
Drugs Effects and Considerations References
Anticonvulsant/Antiepileptic 
Drugs 
They may cause hyper‑homosisteinemia due to the folic acid, vitamin B6, 
vitamin B12 deficiency and MTHFR gene polymorphism. 
Rezaei et al. 2017
Bächle et al. 2015
Munisamy et al. 2015
The use of anticonvulsant drugs with alcohol should be avoided. Vernon 2013
Phenytoin, barbiturates, 
carbamazepine, VPA
They may cause vitamin D deficiency and deteriorate calcium absorption. Baek et al. 2014
Hosseinpour et al. 2007
Vestergaard 2015
They may cause biotin deficiency, low serum and liver biotinides activity. Arslan et al. 2009
Pronsky and Crowe 2012
Rathman et al. 2003
VPA It may cause carnitine deficiency by reducing endogenous  
carnitine synthesis.
Fukuda et al. 2015
Katayama et al. 2016
It may cause hypocalcemia. Davison et al. 2011
It may reduce the serum and hair zinc. Armutcu et al. 2004
Yilmaz et al. 2009
Castro‑Gago et al. 2011
High‑fat diet and soy intake with drug should be avoided. Zhang et al. 2014
Marahatta et al. 2014
Gabapentin, pregabalin, 
carbamazepine and VPA
They may increase body weight by increasing appetite. Antel and Hebebrand 2012
Ben‑Menachem 2007
Pronsky and Crowe 2012
Martin et al. 2009
Levodopa If patients has vitamin B6 and vitamin B12 deficiency or polymorphism in 
MTHFR and MTHFD1 genes, drugs may cause hyperhomocystenaemia.
Xie et al. 2017 
Oliveira et al. 2017 
High protein intake may prevent levodopa to cross blood brain barrier. Aksoy 2016
Ismail 2009
Selective Serotonin Reuptake 
Inhibitors (SSRI)
Fluoxetine It may cause weight loss and decreasing visceral adipose tissue. Aggarwal et al. 2016
Sertraline and paroxetine They was related to high LDL‑ cholesterol, and in the long‑term treatment 
it might pose a risk to cardiovascular disease.
Wei et al. 2009
Citalopram Serum copper levels may reduce in drug users. Schlegel‑Zawadzka and Nowak 2000
Monoamine Oxidase 
Inhibitors (MAOIs) 
It is necessary to avoid consumption of these foods with MAOIs. Flockhart 2012
Aksoy 2016
Pronsky and Crowe 2012
Phenelzine The drug may prevent vitamin B6 to turn into active form. Malcolm et al. 1994
Phenelzine and isocarboxazide Increasing in body weight.
The drugs may increase the appetite.
They may change the energy balance.
McIntyre et al. 2006
Pronsky and Crowe 2012
Ruetsch et al. 2005
Tricyclic Antidepressants 
(TCAs)
Dietary high fiber, legume, fish, meat and vitamin C‑rich foods intake  
may cause a decrease in the absorption of the TCA. 
Pronsky and Crowe 2012
Ismail 2009
It may decrease in the plasma tryptophan concentration and an increase 
in the concentration of tryptophan in the brain.
Eriksson and Walinder 1998
Fekkes et al. 1997
It may increase body weight by stimulating hunger and increasing 
carbohydrate consumption and also influencing the energy balance.
Ruetsch et al. 2005
Antipsychotic Drugs  The drug may increase appetite and body weight. Aksoy 2016
Pronsky and Crowe 2012
Reekie et al. 2015
Kang et al. 2014
Emsley et al. 2015
Chlorpromazine It may cause riboflavin and B12 deficiency. Elmacioğlu 2007
Pronsky and Crowe 2012
Sleeping pills The use of sleeping pills with alcohol and caffeine should be avoided. FDA 2016
Ismail 2009
Zolpidem It may interact with St John’s wort. Hojo et al. 2011
Triazolam It may interact with grapefruit juice. Hukkinen et al. 1995
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MICROBIOTA AND DRUG METABOLISM
Currently, gastrointestinal microbiota is consid‑
ered a potential therapeutic approach for drug discov‑
ery and therapy (Jia et al. 2008). It is well known that 
microbiota are involved in various chemical reactions 
such as acetylation, deacylation, decarboxylation, de‑
hydroxylation, demethylation, and dehalogenation of 
drugs. Moreover, microbiota can shape drug metabo‑
lism of the host indirectly (Wilson and Nicholson 2017). 
In a comprehensive review, Sousa et al. (2008) provided 
an overview of the gastrointestinal microbiota, their 
drug substrates, and metabolic mechanisms. In the re‑
view, they concluded that microbiota should be consid‑
ered in development process of drugs. 
In recent years, gut microbiota and health interac‑
tions have been highlighted as an important emerging 
issue. Several studies have highlighted that different 
patterns of gut microbiota predict better health out‑
comes, and that gut microbiota interact with external 
sources that the host consumes, such as nutrients and 
drugs. Along with age, type of birth, physical activity, 
smoking and antibiotic use, diet pattern is one of the 
major factors that can modulate the gut microbiota 
(Laparra and Sanz 2010). 
Results of recent studies reveal an interaction be‑
tween diet, gut microbiome, and vagal gut‑brain com‑
munication. These studies provide strong evidence for 
the role of food in physiology and pathology of the ner‑
vous system. High fat‑induced diets lead to increased 
body fat accumulation and changes in gut microbi‑
ota (i.e. increased Firmicutes/Bacteriodetes ratio and 
Proteobacteria). High fat diets may also disrupt vagal 
gut‑brain communication via microglia activation, as 
shown recently in Sprague‑Dawley rats (Vaughn et al. 
2017). Furthermore, low fat intake in conjunction with 
high fat and high sugar can alter the composition of 
the microbiota, increase circulating lipopolysaccharide 
levels, and may increase obesity risk via vagal remodel‑
ing (Sen et al. 2017). Given the strong influence of diet 
on the gut microbiota, diet may also alter drug phar‑
macokinetics. 
CONCLUSION
Drugs used in the treatment of neurological and 
psychological diseases can interact with many foods 
and nutrients. As a result of these drug‑food interac‑
tion, the expected outcomes may not be observed. In 
addition, drug toxicity may occur and the nutritional 
status may deteriorate via nutrient deficiencies. Fur‑
thermore, some food/nutrient‑drug interactions may 
cause changes in body weight and energy balance via 
modulation of appetite. Genetic background is one of 
the main determinants of these interactions. In partic‑
ular, neurological and psychological patients with spe‑
cific gene polymorphisms can be at increased risk for 
food‑drug interactions, compared to patients without 
the polymorphism. Moreover, microbiota can shape 
the drug metabolism of the host. Thus, microbiota 
alterations should also be considered while assessing 
diet/nutrient–drug interactions. When considering 
all interaction mechanisms and other related factors, 
prognosis of neurological and psychological diseases 
may deteriorate because of these secondary outcomes. 
Therefore, monitoring for food–drug interactions will 
be critical for determining the appropriate dosage and 
timing of drugs, and preventing adverse secondary out‑
comes. Knowledge of food‑drug interactions is import‑
ant for improving health of patients with neurological 
and psychological diseases, as well as for improving 
the effectiveness of treatments. To prevent food‑drug 
interactions, there should be multidisciplinary collab‑
oration between pharmacists, doctors, nurses and di‑
eticians throughout the duration of the treatment pro‑
tocol. Moreover, a nutrition program/diet prepared by 
a dietician will be helpful in monitoring and prevent‑
ing nutritional deficiencies and body weight changes 
that occur from food‑drug interactions. Taking these 
steps will help minimize adverse effects of food‑drug 
interactions.
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